UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000180
Receipt number R000000253
Scientific Title A pilot phaseII study of 3 dimensional stereotactic radiotherapy (3D-SRT) followed by maintenance therapy with oral UFT for stage IB non - small cell lung cancer
Date of disclosure of the study information 2005/09/12
Last modified on 2018/10/03 14:00:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A pilot phaseII study of 3 dimensional stereotactic radiotherapy (3D-SRT) followed by maintenance therapy with oral UFT for stage IB non - small cell lung cancer

Acronym

Pilot study of 3 dimensional stereotactic radiotherapy and oral UFT for stage IB NSCLC.

Scientific Title

A pilot phaseII study of 3 dimensional stereotactic radiotherapy (3D-SRT) followed by maintenance therapy with oral UFT for stage IB non - small cell lung cancer

Scientific Title:Acronym

Pilot study of 3 dimensional stereotactic radiotherapy and oral UFT for stage IB NSCLC.

Region

Japan


Condition

Condition

non - small cell lung cancer, stageIB.

Classification by specialty

Pneumology Hematology and clinical oncology Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety and efficacy of maintenance therapy with oral UFT for two years from the 57th day after 3 dimensional stereotactic radiotherapy (3D-SRT) for patients with stage IB non - small cell cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

3-year survival

Key secondary outcomes

Progression free survival, median
survival time, local progression free survival time, local progression free survival at 3 years, pattern of progression or recurrence, adverse events, 5-year survival rate, local progression free survival at 5 years


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Oral UFT 250mg/m2 therapy for two years from the 57th day after 3 dimensional stereotactic radiotherapy (3D-SRT) which consists of consecutive 4 days of 12 Gray irradiation per fraction per day (total 48Gy)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >

Gender

Male and Female

Key inclusion criteria

1)Histologically or cytologically confirmed non-small cell lung cancer
2)Stage IB
3)No previous pulmonary irradiation
4)ECOG PS 0-2
5)Measurable lesions(<5cm)
6)Lesion in the lung
7)20<=Age<85
8)Adequate organ function
Hb>10g/dL, 3000/mm31,500/mm3, Platelet count> 12000/mm3, GOT and GPT<100IU/ml, T-bilirubin<2mg/dl, serum creatinine<1.5mg/dl, PaO260>Torr (room air), FEV1.0>700ml, %VC>50%, ejection fraction>60%
9)Life expectancy for more than 6 months
10)An inoperable patient or patient who refuses operation
11)Written informed consent

Key exclusion criteria

1)Apparent interstitial pneumonitis or fibrosis on chest X ray
2)Irradiation field larger than half of a ipsilateral lung
3)Double cancer within 5 years except for carcinoma in situ, intramucosal tumor, and basal cell carcinoma of the skin
4)History of previous chemotherapy
5)Pregnant woman, lactating woman, woman who has a possibility of pregnancy
6)Uncontrolled angina pectoris, myocardial infarction and congestive heart failure within three months
7)Uncontrolled diabetes mellitus
8)Active infectious disease
9)Fever more than 38 degrees Celsius
10)Steroid administration
11)Other complication unsuitable for the study

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Nobuyuki Katakami

Organization

Institute of Biomedical Research and Innovation

Division name

Department of Translational Research Division of Integrated Oncology

Zip code


Address

2-2 Minatomajima-Minamimachi Chuo-ku Kobe 650-0047, Japan

TEL

078-304-5200

Email



Public contact

Name of contact person

1st name
Middle name
Last name Reiko Naya

Organization

Institute of Biomedical Research and Innovation

Division name

Department of Translational Research Division of Integrated Oncology

Zip code


Address

2-2 Minatomajima-Minamimachi Chuo-ku Kobe 650-0047, Japan

TEL

078-304-5200

Homepage URL


Email

naya@kcgh.gr.jp


Sponsor or person

Institute

Institute of Biomedical Research and Innovation

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

None


Other related organizations

Co-sponsor

Kobe City General Hospital
Kobe City West Hospital
Nishikobe Medical Center
Hyogo Medical Center for Adults

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2005 Year 09 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 11 Month 05 Day

Date of IRB


Anticipated trial start date

2004 Year 12 Month 01 Day

Last follow-up date

2011 Year 10 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2005 Year 09 Month 12 Day

Last modified on

2018 Year 10 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000253


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name